MYXREDLIN DIN 02529602
Status: Marketed
Holder: BAXTER CORPORATION
Health Canada record
| Active ingredient(s) | INSULIN (HUMAN) 1 UNIT |
|---|
| Dosage form | Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | A10AB01 INSULIN (HUMAN) |
|---|
| Original market date | 28-Jul-2023 |
|---|
| Current status date | 28-Jul-2023 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Baxter Corporation — licence 100278, currently licensed, last inspection rating C (2026-08-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing INSULIN (HUMAN)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02405202 | PROZINC | BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC. | Suspension | INSULIN (HUMAN) 40 UNIT | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 28702 | 2022-08-03 | New Drug Submission (NDS) | |
Request a quote for MYXREDLIN
How to read a Canadian DIN record